Form D · Biotechnology
BIO-PATH HOLDINGS, INC.
Bellaire, TX · CIK 0001133818
Offering snapshot reported Oct 22, 2024 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 8, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 22, 2024 | Initial | $3,995,403 | No comparison | 1 | SEC filing |
| Jun 13, 2024 | Initial | $3,998,370 | No comparison | 1 | SEC filing |
| Apr 26, 2024 | Initial | $1,275,880 | No comparison | 3 | SEC filing |
| Apr 5, 2024 | Initial | $317,929 | No comparison | 1 | SEC filing |
| Nov 18, 2022 | Initial | $2,280,000 | No comparison | 5 | SEC filing |
| Mar 18, 2019 | Initial | $1,387,514 | No comparison | 4 | SEC filing |
| Jan 25, 2019 | Initial | $987,746 | No comparison | 8 | SEC filing |
| Jan 25, 2019 | Initial | $83,775 | No comparison | 1 | SEC filing |
| Oct 5, 2018 | Initial | $2,301,340 | No comparison | 4 | SEC filing |
| Aug 5, 2013 | Initial | $10,000 | No comparison | 1 | SEC filing |
| May 3, 2013 | Initial | $453,000 | No comparison | 2 | SEC filing |
| Nov 1, 2012 | Amendment | $1,004,101 | $929,101vs May 22, 2012 | 62 | SEC filing |
| May 22, 2012 | Initial | $75,000 | No comparison | 3 | SEC filing |
| Mar 17, 2011 | Amendment | $741,000 | $591,000vs Jan 3, 2011 | 14 | SEC filing |
| Jan 3, 2011 | Initial | $150,000 | No comparison | 4 | SEC filing |
| Jun 9, 2010 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Jun 2, 2010 | Amendment | $923,000 | $923,000vs Jan 8, 2010 | 7 | SEC filing |
| Jan 8, 2010 | Initial | $0 | No comparison | 2 | SEC filing |
| Oct 6, 2009 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| May 12, 2009 | Initial | Yet to sell | No comparison | Not reported | SEC filing |
| Nov 13, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $340K
- Finders' fees
- $0
- Form D file number
- 021-527517
Includes the gross proceeds received in the offering.
H.C. Wainwright & Co., LLC received the above sales commission and warrants to purchase up to an aggregate of 344,828 shares of the Company's common stock, par value $0.001 per share at an exercise price equal to $1.0875 per share as compensation.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Oct 22, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul D. Aubert | Director |
| Heath W. Cleaver | Director |
| Mark P. Colonnese | Director |
| Thomas Garrison | Director |
| Michael Garrison | Director |
| Gillian Ivers Read | Director |
| Douglas P, Morris | Director |
| Peter H. Nielsen | Director, Executive |
| Aline Sherwood | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4710 Bellaire Boulevard Suite 210
Bellaire, TX, 77401
Bellaire, TX, 77401